The Urgent Crisis of Antibiotic-Resistant E. coli Infections in Canada and Beyond
Escherichia coli (E. coli), a bacterium commonly found in the intestines, becomes a serious threat when certain strains evolve into extraintestinal pathogenic E. coli (ExPEC), particularly uropathogenic E. coli (UPEC) responsible for urinary tract infections (UTIs). These infections affect millions annually, leading to complications like kidney infections, sepsis, and even death. Globally, ExPEC-associated UTIs contribute to nearly 250,000 deaths each year, with the mortality rate from UTIs rising 140 percent between 1990 and 2019 due to escalating antibiotic resistance. In Canada, antimicrobial resistance (AMR) claims over 3,000 lives yearly, with E. coli ranking high among priority pathogens monitored by the Canadian Antimicrobial Resistance Surveillance System (CARSS). Resistance to common antibiotics like third-generation cephalosporins in E. coli bloodstream infections has climbed to around 15-17 percent in recent years, complicating treatments and prolonging hospital stays.
The World Health Organization (WHO) classifies E. coli as a 'critical' priority pathogen, projecting that by 2050, AMR deaths could rival those from cancer. In Canada, the Pan-Canadian Action Plan on AMR emphasizes surveillance and innovation, yet challenges persist with rising multidrug-resistant strains in community and hospital settings. UTIs, often dismissed as minor, recur in vulnerable groups—women, children, catheter users, and cancer survivors—leading to urosepsis, a life-threatening bloodstream infection.
This crisis underscores the need for novel therapies beyond traditional antibiotics, which select for resistance. Researchers at the University of Alberta (UAlberta) are at the forefront, offering hope through virulence-targeted strategies that disarm bacteria without killing them outright.
UAlberta's Groundbreaking Discovery: The GlpG Rhomboid Protease as a Novel Drug Target
A multidisciplinary team led by M. Joanne Lemieux, professor of biochemistry at UAlberta, published pivotal research in Nature Communications on December 30, 2025, titled 'Rhomboid protease GlpG regulates type 1 pili quality control and virulence in pathogenic E. coli'. The study identifies GlpG, an intramembrane rhomboid protease embedded in the bacterial inner membrane, as essential for ExPEC virulence. Unlike broad-spectrum antibiotics, targeting GlpG disrupts specific pathogenic mechanisms, potentially minimizing resistance development.
First author Jimmy Lu, a former PhD student in Lemieux's lab now a Mitacs postdoctoral fellow with industry partner Applied Pharmaceutical Innovation, spearheaded experiments revealing GlpG's role. Collaborators spanned UAlberta's departments of biochemistry, medical microbiology, immunology, and pediatrics, alongside experts from the University of Manitoba and University of Calgary. This work builds on prior observations that glpG mutants fail to colonize the murine gut, now mechanistically linked to pili defects.
The discovery highlights UAlberta's strength in membrane protein research, positioning the institution as a leader in Canadian AMR innovation. Lemieux, vice-dean of research for the Faculty of Medicine & Dentistry, emphasized, 'Understanding the virulence factors for pathogenic E. coli is the first step' toward new countermeasures.Learn more about UAlberta faculty research.
How GlpG Functions: Protein Quality Control for Type 1 Pili and Biofilms
Type 1 pili, hair-like appendages on ExPEC surfaces, enable adhesion to host bladder and kidney cells, a prerequisite for infection. Composed primarily of FimA subunits, pili assembly occurs in the periplasm, where misfolded proteins aggregate without proper chaperones. GlpG cleaves these soluble aggregates, preventing jams and ensuring mature pili export.
- Proteomics revealed GlpG interacts with FimA and chaperones like FimC, DegP, and DegQ.
- In glpG mutants or inhibited strains, FimA aggregates accumulate, halting pili formation (confirmed by transmission electron microscopy and hemagglutination assays).
- This cascades to reduced biofilm production—sticky matrices shielding bacteria from antibiotics and immunity—critical for chronic UTIs.
Traditionally, rhomboid proteases like GlpG cleaved transmembrane substrates; this study expands the paradigm to periplasmic quality control, validated by in vitro cleavage assays and rescue experiments. Inhibiting GlpG with TPCK (tosyl phenylalanyl chloromethyl ketone) mimicked mutants: no invasion in cell lines or kidney organoids, eradicated biofilms without toxicity.
Experimental Breakthroughs: Disarming E. coli Virulence Step-by-Step
The UAlberta team employed CRISPR/Cas9 to generate glpG catalytic-dead mutants (S201A), proteomics via mass spectrometry on pulldowns, and functional assays:
| Assay | Key Result |
|---|---|
| Gentamicin Protection (Invasion) | 80-90% reduction in bladder/kidney cell invasion |
| Biofilm Quantification (Safranin) | GlpG inhibition prevents/eradicated biofilms on abiotic/biotic surfaces |
| Organoid Infection | No intracellular bacteria in kidney organoids |
| FRET Cleavage | GlpG directly processes FimA aggregates |
These findings confirm GlpG's non-redundant role, positioning it as an antivirulence target. Unlike bactericidal drugs, inhibition attenuates fitness without strong resistance pressure.
For Canadian researchers, this validates structural biology's role in drug discovery, with UAlberta's facilities like the Canadian Centre for Structural Biology accelerating progress.
Profiles of Innovation: M. Joanne Lemieux and the UAlberta Team
M. Joanne Lemieux, executive director of the PRAIRIE Hub for Pandemic Preparedness, brings expertise from virology (SARS-CoV-2 protease inhibitors) to bacteriology. Her lab, funded by NSERC, CFI, and provincial foundations, holds patents ripe for translation. Jimmy Lu's thesis work exemplifies PhD training at UAlberta, bridging academia-industry via Mitacs.
Team members like Wael Elhenawy (microbiology) and Eytan Wine (pediatrics) provide clinical insights, reflecting interdisciplinary higher ed at UAlberta. Rate professors like Lemieux and explore careers in higher ed research jobs.
Treatment Implications: Revolutionizing UTI Management in Canada
Canada sees millions of UTIs yearly, with ExPEC causing 80-90% of community cases. AMR complicates empiric therapy; 20% resistance to first-line drugs like trimethoprim-sulfamethoxazole. GlpG inhibitors could complement antibiotics, preventing recurrence in high-risk groups—pediatrics, elderly, immunocompromised.
Beyond UTIs, ExPEC links to Crohn's, IBD, and stent blockages. Protease inhibitors' precedent (HIV protease drugs) shortens pipelines (5-10 years vs. 15). UAlberta aims for selective inhibitors sparing commensal E. coli, preserving gut health.Read the full Nature Communications paper.
This aligns with Canada's AMR Action Plan, fostering academic careers in infectious disease research.
Canada's AMR Landscape: E. coli Challenges and National Responses
CARSS 2025 reports E. coli as top Gram-negative threat, with rising carbapenemase producers. Prevalence: 10-20% ESBL resistance in clinical isolates. Deaths: AMR-attributable ~1,200/year from E. coli infections. Zoonotic links (poultry) heighten surveillance needs.
- One Health approach: Monitor food-animal-human transmission.
- Stewardship: Provincial guidelines reduce overuse.
- Innovation: CIHR funds target discovery.
UAlberta contributes via WCHRI and Li Ka Shing Virology Institute.
Explore CARSS data.From Bench to Bedside: UAlberta's Path to New E. coli Therapies
Lemieux's lab leverages pandemic-honed inhibitor design for GlpG. Next: High-throughput screening, structural optimization (cryo-EM/X-ray), preclinical models. Partnerships with Applied Pharmaceutical Innovation accelerate translation.
Challenges: Selectivity, delivery to periplasm. Opportunities: Repurpose existing proteases for UTIs. UAlberta's ecosystem supports startups via higher ed jobs in biotech.
Broader Impacts: Advancing Canadian Higher Education and Public Health
This discovery elevates UAlberta's global profile, attracting talent and funding. It exemplifies how university research drives AMR solutions, vital amid 2025 CARSS priorities. Students gain hands-on training in proteomics, organoids—skills for faculty positions or industry.
Stakeholders: Patients benefit from fewer surgeries; policymakers from evidence for investment; vets from One Health insights. Future: Integrate into national UTI guidelines.
Future Outlook and Calls to Action for Researchers and Students
Optimism tempers urgency: GlpG validates antivirulence paradigm, but sustained funding needed. UAlberta calls for collaboration. Aspiring scientists, pursue research assistant jobs or postdoc advice. Explore openings at university jobs, higher ed jobs, rate my professor, and career advice.
Lemieux warns, 'UTI is an infectious disease that’s so common people take for granted that there’s going to be an antibiotic there for them.' This UAlberta breakthrough paves the way for safer, effective treatments, safeguarding Canadian health.
Discussion
Be the first to comment on this article!
You’ll be asked to sign in before your comment is posted.